“…Therefore, APOs has been used to validate the onset of Parkinson's disease symptoms in rat models [10], [11]. Generally, inhibiting dopamine transmission results in elevated beta oscillations (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30) and enhanced spike firing rates in the STN [12], [13]. More recently, studies have reported the possibility of recordings about oscillatory and spike activity in this PD model using microelectrode arrays (MEAs).…”